British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

A LUNG virus that can be deadly in babies has plummeted by 72 per cent thanks to a new vaccine. It’s the first real world data showing the effectiveness of the RSV jab – but figures ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Vaccination of pregnant women has been linked to a drop in newborns being admitted to hospital with a serious lung infection, ...

The Centers for Disease Control and Prevention (CDC) recommends that pregnant women receive an RSV vaccine during their third ...

RSV has outstripped severe Covid and flu hospitalisation rates and proved itself more fatal than either of the flu season ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

Blog - A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.

A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.